Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

详细信息    查看全文

• 作者：Shigeaki Suzuki^a ; ^{sgsuzuki@z3.keio.jp} ; Tetsuya Nishimoto^b ; ^{nishi0322@gmail.com} ; Mitsutomo Kohno^c ; ^{kohno@a3.keio.jp} ; Kimiaki Utsugisawa^d ; ^{kutsugi@s4.dion.ne.jp} ; Yuriko Nagane^d ; ^{yrnagane@yahoo.co.jp} ; Masataka Kuwana^b ; ^{kuwanam@z5.keio.jp} ; Norihiro Suzuki^a ; ^{nrsuzuki@a2.keio.jp}
• 关键词：Myasthenia gravis ; Thymoma ; Prognosis ; Anti-Kv1.4 antibody
• 刊名：Journal of Neuroimmunology
• 出版年：2013
• 出版时间：15 May, 2013
• 年：2013
• 卷：258
• 期：1-2
• 页码：61-66
• 全文大小：401 K

文摘

There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.